Corbus Pharmaceuticals Q2 EPS $(2.05) Beats $(3.10) Estimate
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals reported Q2 losses of $(2.05) per share, beating the analyst consensus estimate of $(3.10) by 33.87 percent. This represents a 2.38 percent increase over losses from the same period last year.
August 08, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corbus Pharmaceuticals reported better than expected Q2 losses, which could positively impact the stock in the short term.
Corbus Pharmaceuticals reported Q2 losses that were less than the analyst consensus estimate. This beat of estimates is typically viewed positively by the market and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100